Monday, December 5, 2016

BRIEF-Juno therapeutics presents data from TRANSCEND study

* Juno Therapeutics presents data from TRANSCEND study

showing 60% complete response in patients with relapsed or

refractory aggressive CD19+ non-hodgkin lymphoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)